These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8437372)

  • 1. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro.
    Nomoto K; Saeki T; Kogushi M; Kobayashi H; Fujimori T; Yamatsu I
    Jpn J Pharmacol; 1993 Jan; 61(1):7-12. PubMed ID: 8437372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new anti-platelet drug, E5510, has multiple suppressive sites during receptor-mediated signal transduction in human platelets.
    Fujimori T; Harada K; Saeki T; Kogushi M; Yoshimura T; Katayama K
    Jpn J Pharmacol; 1991 Jan; 55(1):81-91. PubMed ID: 1645815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
    Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
    Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
    Reilly MP; Moran N; Meagher E; Delanty N; Cucchiara AE; Lawson JA; Catella-Lawson F
    J Cardiovasc Pharmacol; 1999 Jan; 33(1):12-8. PubMed ID: 9890391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs.
    Fujioka K; Esato K; Furutani A; Akiyama N; Yoshimura K; Takenaka H; Sekido T; Suganuma A; Sagami F
    J Cardiovasc Pharmacol; 1996 Jun; 27(6):824-30. PubMed ID: 8761849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological aspects of a novel antiplatelet drug, E5510].
    Ikeda Y
    Nihon Rinsho; 1992 Feb; 50(2):366-71. PubMed ID: 1613992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of E5510, a novel antiplatelet agent, on platelet deposition in atherothrombotic lesions: evaluation by 111In platelet scintigraphy.
    Moriwaki H; Matsumoto M; Handa N; Hashikawa K; Hori M; Nishimura T
    Nucl Med Commun; 2000 Nov; 21(11):1051-8. PubMed ID: 11192711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid.
    Fujimori T; Harada K; Saeki T; Kogushi M; Akasaka K; Yamagishi Y; Yamatsu I
    Arzneimittelforschung; 1987 Oct; 37(10):1143-8. PubMed ID: 3124862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibition of canine vein graft intimal thickening using a newly developed antiplatelet agent.
    Mawatari K; Komori K; Kuma S; Okazaki J; Kawasaki K; Eguchi D; Itoh H; Onohara T; Sugimachi K
    J Cardiovasc Surg (Torino); 1997 Aug; 38(4):359-65. PubMed ID: 9267344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets.
    Barradas MA; Jagroop IA; Mikhailidis DP
    Clin Chim Acta; 1994 Oct; 230(2):157-67. PubMed ID: 7834867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
    Alarayyed NA; Prichard BN; Betteridge DJ; Smith CC
    Platelets; 2002; 13(5-6):267-71. PubMed ID: 12189011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E5510 antagonizes thrombin receptor signals by inhibiting NF-kappa B activation.
    Nakajima T; Kitajima I; Shin H; Matsumoto W; Soejima Y; Maruyama I
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1181-7. PubMed ID: 8093037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphine-potentiated agonist-induced platelet aggregation through alpha2-adrenoceptors in human platelets.
    Sheu JR; Yeh GC; Fang CL; Lin CH; Hsiao G
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):743-50. PubMed ID: 12409983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CAPE analogue as novel antiplatelet agent efficiently inhibits collagen-induced platelet aggregation.
    Zhou K; Li X; Du Q; Li D; Hu M; Yang X; Jiang Q; Li Z
    Pharmazie; 2014 Aug; 69(8):615-20. PubMed ID: 25158573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of reduced glutathione on platelet function.
    Pacchiarini L; Tua A; Grignani G
    Haematologica; 1996; 81(6):497-502. PubMed ID: 9009436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDGF modifies phosphoinositide metabolism and inhibits aggregation and release in human platelets.
    Bryckaert MC; Rendu F; Tobelem G; Caen J
    Biochem Biophys Res Commun; 1986 Feb; 135(1):52-7. PubMed ID: 3006686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
    Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
    Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-heparin hemodialysis with oral administration of newly developed antiplatelet agent.
    Teraoka S; Takahashi K; Suzuki T; Naganuma S; Mineshima M; Hoshino T; Era K; Sanaka T; Agishi T; Ota K
    ASAIO Trans; 1990; 36(3):M212-5. PubMed ID: 2252660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: possible mechanism for antiplatelet action.
    Sugidachi A; Breiter N; Ogawa T; Asai F; Koike H
    Thromb Haemost; 1996 Nov; 76(5):786-90. PubMed ID: 8950791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.